A phase II study of brentuximab vedotin in patients with relapsed or refractory Epstein-Barr virus-positive and CD30-positive lymphomas

Miso Kim,1,2 Jeong-Ok Lee,3 Jiwon Koh,4 Tae Min Kim,5,6 Ji Yun Lee,3 Yoon Kysung Jeon,6,7 Bhum suk Keam,5,6 Dong-Wan Kim,5,6 Jong Seok Lee3 and Dae Seog Heo1,2

1Department of Internal Medicine, Seoul National University Hospital, Seoul, Republic of Korea; 2Seoul National University Cancer Research Institute, Seoul, Republic of Korea; 3Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, Republic of Korea and 4Department of Pathology, Seoul National University Hospital, Seoul, Republic of Korea.

Correspondence: TAE MIN KIM - gabriel9@snu.ac.kr
doi:10.3324/haematol.2021.278301
## Supplementary Tables

### Supplementary Table S1. Patients’ characteristics

| Characteristics | No. of patients (%) |
|-----------------|---------------------|
| **Age**         |                     |
| ≤ 60 years      | 11 (78.6)           |
| > 60 years      | 14 (21.4)           |
| **Sex**         |                     |
| Male            | 20 (80.0)           |
| Female          | 5 (20.0)            |
| **Diagnosis**   |                     |
| EBV-positive mature T/NK-cell neoplasms | |
| Angioimmunoblastic T-cell lymphoma | 10 (40.0) |
| EBV-positive peripheral T-cell lymphoma, NOS | 5 (20.0) |
| Extranodal NK/T-cell lymphoma, nasal type | 4 (16.0) |
| Hydroa vacciniform-like T-cell lymphoma | 1 (4.0) |
| Mycosis fungoides | 1 (4.0) |
| EBV-positive T-cell LPDs | 1 (4.0) |
| EBV-positive mature B-cell neoplasms | |
| EBV-positive DLBCL of the elderly | 2 (8.0) |
| B cell lymphoma, unclassifiable, with features intermediate between DLBCL and cHL | 1 (4.0) |
| **CD30 expression** |               |
| Low (1 – <10%) | 13 (52.0) |
| Intermediate (10 – <50%) | 5 (20.0) |
| High (≥ 50%)   | 7 (28.0)           |
| **Ann Arbor stage at initial diagnosis** |  |
| Stage | Count (%) |
|-------|-----------|
| II    | 1 (4.0)   |
| III   | 7 (28.0)  |
| IV    | 17 (68.0) |

**ECOG Performance status**

| ECOG Performance status | Count (%) |
|-------------------------|-----------|
| 0                       | 2 (8.0)   |
| 1                       | 23 (92.0) |

**IPI scores**

| IPI scores | Count (%) |
|------------|-----------|
| 0–1        | 6 (24.0)  |
| 2          | 7 (28.0)  |
| 3          | 7 (28.0)  |
| 4–5        | 5 (20.0)  |

**Prior lines of therapy**

| Prior lines of therapy | Count (%) |
|------------------------|-----------|
| 1                      | 10 (40.0) |
| 2                      | 9 (36.0)  |
| ≥3                     | 6 (24.0)  |

Abbreviations: EBV, Epstein-Barr virus; DLBCL, diffuse large B-cell lymphoma; cHL, classical Hodgkin lymphoma; LPD, lymphoproliferative disorder; ECOG, Eastern Cooperative Oncology Group; IPI, International Prognostic Index
Supplementary Table S2. Treatment-related Adverse Events

| Toxicities             | Total N (%) | Grade 1 | Grade 2 | Grade 3 | Grade 4 |
|------------------------|-------------|---------|---------|---------|---------|
| Peripheral neuropathy  | 12 (48)     | 8       | 4       | 0       | 0       |
| Neutropenia            | 10 (40)     | 0       | 5       | 3       | 2       |
| Thrombocytopenia       | 5 (20)      | 0       | 2       | 1       | 2       |
| Rash                   | 4 (16)      | 3       | 1       | 0       | 0       |
| Alopecia               | 3 (12)      | 3       | 0       | 0       | 0       |
| Fatigue                | 3 (12)      | 3       | 0       | 0       | 0       |
| Anemia                 | 2 (8)       | 0       | 0       | 2       | 0       |
| Decreased appetite     | 2 (8)       | 2       | 0       | 2       | 0       |
| Pruritus               | 2 (8)       | 1       | 1       | 0       | 0       |
| Diarrhea               | 1 (4)       | 0       | 1       | 0       | 0       |
| Dizziness              | 1 (4)       | 1       | 0       | 0       | 0       |
| Hyperglycemia          | 1 (4)       | 1       | 0       | 0       | 0       |
| Epigastric discomfort  | 1 (4)       | 1       | 0       | 0       | 0       |
| Asthenia               | 1 (4)       | 1       | 0       | 0       | 0       |
| Pneumonitis            | 1 (4)       | 1       | 0       | 0       | 0       |
| Headache               | 1 (4)       | 1       | 0       | 0       | 0       |
| Nail change            | 1 (4)       | 1       | 0       | 0       | 0       |
| Nausea                 | 1 (4)       | 1       | 0       | 0       | 0       |
| Urinary retention      | 1 (4)       | 1       | 0       | 0       | 0       |
| Sore throat            | 1 (4)       | 1       | 0       | 0       | 0       |
| Thirst                 | 1 (4)       | 1       | 0       | 0       | 0       |
Supplementary Figures

**Figure S1.** Kaplan-Meier plots for (A) progression-free survival, (B) overall survival, (C) progression-free survival according to soluble CD30, and (d) overall survival according to soluble CD30.
Figure S1 (A)

Figure S1 (B)
Figure S1 (C)

![Figure S1 (C)](image)

Figure S1 (D)

![Figure S1 (D)](image)